Pause or continue? study tests ACE inhibitor timing to prevent kidney damage
NCT ID NCT07184918
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looked at whether continuing or temporarily stopping the blood pressure medicine Ramipril (an ACE inhibitor) before coronary angiography affects the risk of kidney injury from the contrast dye. 44 adults were randomly assigned to either keep taking their usual dose or stop it 48 hours before and restart 72 hours after the procedure. Researchers measured kidney function and injury markers to see which approach is safer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ramipril (an ACE inhibitor)
What this could lead to
If it works, this could help doctors decide whether to pause ACE inhibitors before angiography to protect kidneys.
What could go wrong
This is a small, completed study with only 44 people, so results may not apply to everyone. It does not test a new treatment, just compares two approaches.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Faculty of Pharmacy Tanta university
Tanta, Gharbia Governorate, 31527, Egypt